At a glance
ClinicalIndex Comparison RecordPhase 2Active· 40 enrolled
Drug / intervention
ADT+Docetaxel+Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating ADT+Docetaxel+Enzalutamide for Prostate Cancer and Prostate Adenocarcinoma. Active but no longer recruiting, targeting 40 participants across 1 site.
Detailed Summary
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostate Adenocarcinoma
CountriesUnited States
CollaboratorsAstellas Pharma Inc, Medivation, Inc.
Timeline
Phase 2Active
20182019202020212022202320242025202620272028
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionSep 2022
TodayJul 2026
Study CompletionMar 2028
First PostedAug 11, 2017
Enrollment StartAug 23, 2017
Primary CompletionSep 1, 2022
Study CompletionMar 1, 2028
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.9 years ago
Interventions
ADT+Docetaxel+Enzalutamidedrug
combination therapy as listed above